Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Fluoxetine
Focused body repetitive behavior
Nail tic disorders
Obsessive–compulsive disorder
Onychotillomania
Paroxetine
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
20 Nov 2022
20 Nov 2022
Historique:
received:
05
07
2022
accepted:
14
10
2022
entrez:
19
11
2022
pubmed:
20
11
2022
medline:
23
11
2022
Statut:
epublish
Résumé
Obsessive-compulsive disorder is a condition in which patients experience an obsession and/or a compulsion. It has a high impact on the quality of life, and is associated with an increased prevalence of psychiatric comorbidities in patients. Onychotillomania is an underestimated psychodermatosis caused by repeated self-inflicted damage to the nail unit. In patients, it is characterized by an obsessive or irrepressible impulse to repeatedly damage their own nails, resulting in their destruction. It is a chronic condition that is difficult to manage, largely because of its psychocutaneous character, as well as its high tendency to interact with underlying neuropsychiatric diseases or other behavioral disorders. Only a few studies have reported an association between obsessive-compulsive disorder and onychotillomania, which typically presents with therapeutic challenges. Cognitive behavioral therapy, physical-barrier approaches, and pharmaceutical treatments have been reported to be beneficial in the management of onychotillomania; however, no major clinical studies have investigated the effectiveness of these therapies. Onychotillomania remains a clinical and therapeutic issue owing to the lack of evidence-based treatment techniques. We report a case of an 18-year-old, middle-eastern female patient who developed onychotillomania when she was being treated with paroxetine for obsessive-compulsive disorder and was showing partial improvement. The patient developed side effects from paroxetine, and was switched to fluoxetine. Thereafter, improvement in her obsessive-compulsive disorder was observed, which relapsed when treatment was discontinued. However, the onychotillomania symptoms did not reemerge. Onychotillomania typically presents both diagnostic and therapeutic challenges. Fluoxetine plays an important role in the treatment of onychotillomania and other psychiatric disorders. However, large-scale studies should be conducted before these outcomes can be generalized.
Sections du résumé
BACKGROUND
BACKGROUND
Obsessive-compulsive disorder is a condition in which patients experience an obsession and/or a compulsion. It has a high impact on the quality of life, and is associated with an increased prevalence of psychiatric comorbidities in patients. Onychotillomania is an underestimated psychodermatosis caused by repeated self-inflicted damage to the nail unit. In patients, it is characterized by an obsessive or irrepressible impulse to repeatedly damage their own nails, resulting in their destruction. It is a chronic condition that is difficult to manage, largely because of its psychocutaneous character, as well as its high tendency to interact with underlying neuropsychiatric diseases or other behavioral disorders. Only a few studies have reported an association between obsessive-compulsive disorder and onychotillomania, which typically presents with therapeutic challenges. Cognitive behavioral therapy, physical-barrier approaches, and pharmaceutical treatments have been reported to be beneficial in the management of onychotillomania; however, no major clinical studies have investigated the effectiveness of these therapies. Onychotillomania remains a clinical and therapeutic issue owing to the lack of evidence-based treatment techniques.
CASE PRESENTATION
METHODS
We report a case of an 18-year-old, middle-eastern female patient who developed onychotillomania when she was being treated with paroxetine for obsessive-compulsive disorder and was showing partial improvement. The patient developed side effects from paroxetine, and was switched to fluoxetine. Thereafter, improvement in her obsessive-compulsive disorder was observed, which relapsed when treatment was discontinued. However, the onychotillomania symptoms did not reemerge.
CONCLUSION
CONCLUSIONS
Onychotillomania typically presents both diagnostic and therapeutic challenges. Fluoxetine plays an important role in the treatment of onychotillomania and other psychiatric disorders. However, large-scale studies should be conducted before these outcomes can be generalized.
Identifiants
pubmed: 36403006
doi: 10.1186/s13256-022-03652-9
pii: 10.1186/s13256-022-03652-9
pmc: PMC9675954
doi:
Substances chimiques
Fluoxetine
01K63SUP8D
Paroxetine
41VRH5220H
Pharmaceutical Preparations
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
431Informations de copyright
© 2022. The Author(s).
Références
J Cutan Pathol. 2013 Apr;40(4):419-23
pubmed: 23398617
Aust N Z J Psychiatry. 2017 Nov;51(11):1158-1159
pubmed: 28605935
Can J Psychiatry. 2009 May;54(5):331-43
pubmed: 19497165
Psychosomatics. 2001 Jul-Aug;42(4):314-9
pubmed: 11496020
Am J Clin Dermatol. 2017 Dec;18(6):763-770
pubmed: 28488241
J Anxiety Disord. 2014 Mar;28(2):211-4
pubmed: 24291396
Skin Appendage Disord. 2019 Feb;5(2):104-107
pubmed: 30815444
Ann Gen Hosp Psychiatry. 2004 Feb 12;3(1):2
pubmed: 14962351
Indian J Dermatol Venereol Leprol. 2017 Jan-Feb;83(1):19-26
pubmed: 27320768
Indian J Dermatol Venereol Leprol. 2018 Nov-Dec;84(6):652-659
pubmed: 30246706
Psychosomatics. 1993 Mar-Apr;34(2):177-81
pubmed: 8456163
Dermatol Ther. 2003;16(2):114-22
pubmed: 12919113
Skin Appendage Disord. 2020 Jun;6(3):158-161
pubmed: 32656235
Dermatol Clin. 1996 Jul;14(3):509-23
pubmed: 8818561
Arch Dermatol. 2010 Nov;146(11):1222-3
pubmed: 21079056
Transl Pediatr. 2020 Feb;9(Suppl 1):S76-S93
pubmed: 32206586
Encephale. 2001 May-Jun;27(3):280-9
pubmed: 11488259
Acta Derm Venereol. 2014 Jan;94(1):67-71
pubmed: 23756561
Pediatr Dermatol. 1991 Jun;8(2):107-13
pubmed: 1923977
CNS Spectr. 2018 Feb;23(1):59-66
pubmed: 28300008
J Am Acad Dermatol. 2016 Dec;75(6):1245-1250
pubmed: 27473457
Acta Derm Venereol. 2014 Nov;94(6):745-6
pubmed: 24514910
Clin Exp Dermatol. 2006 Jul;31(4):597-9
pubmed: 16716176
Indian J Psychiatry. 2005 Oct;47(4):241-2
pubmed: 20711317
Arch Dermatol. 1992 Mar;128(3):381-8
pubmed: 1550372
Indian J Psychiatry. 2016 Jan-Mar;58(1):98-9
pubmed: 26985115
Int J Environ Res Public Health. 2022 Mar 13;19(6):
pubmed: 35329078
Arch Pediatr Adolesc Med. 2007 Nov;161(11):1026-34
pubmed: 17984403
J Am Acad Child Adolesc Psychiatry. 2001 Jul;40(7):773-9
pubmed: 11437015
AMA Arch Derm Syphilol. 1951 Jun;63(6):778-80
pubmed: 14829063
J Clin Psychiatry. 1997 Aug;58(8):341-7
pubmed: 9515971
J Am Acad Dermatol. 2018 Oct;79(4):702-705
pubmed: 29660424
J Am Acad Dermatol. 2017 Nov;77(5):e143-e144
pubmed: 29029927
Behav Res Ther. 2008 Sep;46(9):1040-6
pubmed: 18692168
Br J Psychiatry. 2000 May;176:421-8
pubmed: 10912216
Cutis. 2004 Mar;73(3):171-4
pubmed: 15074344
Arch Dermatol. 1997 Oct;133(10):1203-4
pubmed: 9382557